PPA
OGEN icon

Parametric Portfolio Associates’s Oragenics OGEN Stock Holding History

Parametric Portfolio Associates’s Portfolio OGEN Stock Details OGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2
Closed -$13K – 4022
2017
Q1 		$13K Buy
+2
New +$21.5K ﹤0.01% 3771

Other funds holding OGEN

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Parametric Portfolio Associates's OGEN Position: Q2 2017 in Review

Parametric Portfolio Associates sold out of Oragenics (OGEN) in Q2 2017, closing a stake of 2 shares — an estimated $13K sold.

Parametric Portfolio Associates first reported a position in OGEN in Q1 2017 and held it in 1 quarter. The position peaked at $13K in Q1 2017. 12 funds tracked by Wall St. Rank hold OGEN as of Q2 2017.

  • Parametric Portfolio Associates reported no remaining Oragenics position as of Q2 2017 after selling out during the quarter.
  • Parametric Portfolio Associates sold 2 Oragenics shares in Q2 2017, an estimated $13K.
  • Parametric Portfolio Associates first reported a position in Oragenics in Q1 2017 and held it in 1 quarter.
  • Parametric Portfolio Associates's Oragenics position peaked at $13K in Q1 2017.
  • 12 funds tracked by Wall St. Rank held Oragenics as of Q2 2017.

Based on Parametric Portfolio Associates's 13F filing for Q2 2017, filed 11 Aug 2017.